
Migraine drug is first to tackle debilitating early symptoms
Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity
Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity
Researchers looking to study the social ramifications of mass traumas must not overlook the histories of affected communities in the search for healing.
The steepest drops in number are seen in areas that host the largest populations — a trend observed for more than 80% of bird species across the continent.